Jump to content

SNG-12

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
SNG-12
Clinical data
Other namesSNG12; SNG 12; Synapsinae
Drug classGlycine transporter 1 (GlyT1) inhibitor; Glycine reuptake inhibitor

SNG-12, also known as Synapsinae, is a glycine transporter 1 (GlyT1) inhibitor, or a glycine reuptake inhibitor, which is under development for the treatment of psychotic disorders, dementia, depressive disorders, and suicidal ideation.[1][2][3] As of September 2022, it is in phase 3 clinical trials for depressive disorders and suicidal ideation and is in phase 2 clinical rials for psychotic disorders and dementia.[1][2][3] The drug is under development by SyneuRx.[1][2] It is described as a small molecule, but its chemical structure does not appear to have been disclosed.[1][2][4]

See also

References

  1. ^ a b c d "SNG 12". AdisInsight. 23 September 2022. Retrieved 21 October 2024.
  2. ^ a b c d "Delving into the Latest Updates on Synapsinae with Synapse". Synapse. 28 September 2024. Retrieved 21 October 2024.
  3. ^ a b "A phase III study for SNG-12 in depression and Suicidal ideation". AdisInsight. 16 March 2021. Retrieved 21 October 2024.
  4. ^ "Synapsinae Drug Profile". Ozmosi. 7 May 2024. Retrieved 21 October 2024.